SCHEMBL30058168

SCHEMBL30058168

OCCCCn1cnc2ccccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.70
▸ SMN1; SMN2 Q16637 8/20 0.65
▸ LMNA P02545 5/20 0.65
▸ TSHR P16473 2/20 0.65
▸ ALOX15 P16050 1/20 0.65
▸ EGLN3 Q9H6Z9 1/20 0.59
▸ HTT P42858 6/20 0.58
▸ MAPT P10636 4/20 0.58
▸ STAT3 P40763 1/20 0.58
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ NPC1 O15118 1/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ NFKB2 Q00653 1/20 0.56
▸ RELA Q04206 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ DRD2 P14416 2/20 0.54
▸ DRD4 P21917 2/20 0.54
▸ DRD3 P35462 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5610837 1.00 TDP1 (0.70) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL14740042 0.98 TDP1 (0.68) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL5888624 0.98 TDP1 (0.68) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL5610799 0.98 TDP1 (0.68) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL825505 0.95 TDP1 (0.72) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL3161153 0.91 TDP1 (0.84) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL9814241 0.89 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL352046 0.89 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15
Ammonia Solution, Strong SCHEMBL7100443 0.89 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL353009 0.89 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220363640-A1 ANTIVIRAL COMPOUNDS Janssen Biopharma, Inc. (US) 2022-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363640-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 TDP1 1724/4885SMN1; SMN2 1041/4885LMNA 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback